Introduction

In a closely watched pharmaceutical patent dispute, Alkermes, PLC and Nanjing Delova Biotech Co., Ltd. reached a settlement agreement in the U.S. District Court for the District of New Jersey, administratively terminating Case No. 2:23-cv-09763 on August 6, 2024 — just under one year after filing. The case centered on four U.S. patents protecting ANJESO® (meloxicam injection, 30 mg/mL), a non-opioid injectable analgesic approved by the FDA for postsurgical pain management.

This pharmaceutical patent infringement case reflects a recurring and strategically significant dynamic: an established U.S. biopharmaceutical patent holder moving swiftly and aggressively to protect its branded injectable product against an emerging biotech competitor. For patent attorneys, IP professionals, and R&D teams operating in the injectable analgesic or specialty pharmaceutical space, this case offers concrete lessons in patent assertion strategy, venue selection, and the commercial calculus that drives pharmaceutical litigation toward settlement.

Case Overview

The Parties

The Patents at Issue

Four U.S. patents formed the basis of Alkermes’ infringement claims. These patents collectively cover formulation, dosing, and administration technology related to injectable meloxicam — specifically the 30 mg/mL concentration used in ANJESO®.

• • US10881663B2 — Meloxicam formulation
• • US11458145B2 — Dosing and administration method
• • US10709713B2 — Injectable meloxicam composition
• • US9974746B2 — Pharmaceutical formulations

Litigation Timeline & Procedural History

Alkermes filed the complaint on **August 24, 2023**, in the **U.S. District Court for the District of New Jersey** — a deliberate and strategically important venue choice. New Jersey is home to one of the most active pharmaceutical patent litigation dockets in the country, with judges experienced in complex ANDA and drug formulation disputes. The district’s familiarity with Hatch-Waxman litigation and specialty pharmaceutical IP makes it a preferred forum for branded drug patent enforcement.

The case proceeded at the first-instance (district court) level and resolved without reaching trial, summary judgment, or published claim construction rulings. The **348-day duration** is consistent with pharmaceutical patent cases that reach early settlement — often after initial pleadings, discovery negotiations, and the recognition by both parties that settlement may offer commercial terms superior to protracted litigation risk.

The Court’s August 6, 2024 order administratively terminated the action while preserving the parties’ right to file dismissal papers within 90 days under Federal Rule of Civil Procedure 41, or to reopen the case if settlement could not be consummated.

The Verdict & Legal Analysis

Outcome

The case was **resolved through settlement** and administratively terminated by court order on August 6, 2024. The settlement terms — including any licensing arrangements, financial consideration, or market entry restrictions — were not publicly disclosed. No damages award was entered, and no injunctive relief was issued by the court. Absent the filing of formal dismissal papers or a motion to reopen within 90 days, the court’s order provides for dismissal **with prejudice and without costs**.

Verdict Cause Analysis

The action was filed as a straightforward **patent infringement claim** under 35 U.S.C. § 271. While the case settled before any substantive merits rulings, the filing itself carries analytical weight. Alkermes asserted four patents — spanning multiple application numbers across the same general patent family — signaling a comprehensive infringement theory rather than a targeted single-patent assertion.

The multi-patent assertion strategy is common in branded pharmaceutical litigation where the IP holder seeks to maximize both the scope of infringement exposure and the cost calculus for the defendant. By asserting patents covering different aspects of the meloxicam injectable technology, Alkermes created overlapping validity and infringement defenses that Nanjing Delova would need to address simultaneously.

No claim construction orders, invalidity rulings, or expert opinions were entered into the public record given the pre-trial resolution.

Legal Significance

While this case produced no published opinions, its settlement carries implicit precedential weight for companies in the injectable NSAID and specialty pharmaceutical space. The willingness of Alkermes to pursue a Chinese biotech firm through U.S. federal court underscores the enforceability of U.S. pharmaceutical patent rights against international competitors targeting the American market.

The case also reflects the strategic reality that pharmaceutical companies often build **patent thickets** — dense layers of overlapping IP protection — around commercially valuable drug formulations. The four-patent portfolio here exemplifies this approach.

Strategic Takeaways

For Patent Holders: Layered patent portfolios covering formulation, concentration, and administration method provide meaningful litigation leverage. Asserting multiple patents across a family increases settlement pressure and complicates invalidity defenses.

For Accused Infringers: Early case evaluation is critical. International biotech companies entering the U.S. market must conduct rigorous **Freedom to Operate (FTO) analysis** before commercialization — particularly in therapeutic areas with established branded products and dense IP portfolios.

For R&D Teams: Injectable drug formulations with approved FDA indications are surrounded by robust patent protection that extends well beyond composition-of-matter claims. Engineers and formulators must assess process patents, dosing method claims, and formulation-specific claims before advancing analogous development programs.

Industry & Competitive Implications

The Alkermes v. Nanjing Delova case sits at the intersection of two significant pharmaceutical market trends: the global expansion of Chinese biotechnology companies into U.S. markets, and the intensifying IP enforcement environment surrounding non-opioid analgesics.

ANJESO® represents Alkermes’ strategic play in the postsurgical pain management market — a space under policy and commercial pressure to reduce opioid utilization. Protecting that market position through aggressive IP enforcement is commercially rational. The decision to litigate rather than issue an early cease-and-desist or initiate licensing discussions reflects the perceived commercial threat of Nanjing Delova’s competing product.

For the broader pharmaceutical industry, this case reinforces that **U.S. patent enforcement extends globally** — international manufacturers selling into or seeking to enter the U.S. market face full exposure to domestic patent litigation. Chinese biotech companies, in particular, must resource U.S.-qualified IP counsel and implement robust pre-market FTO strategies.

The settlement resolution — rather than adjudicated victory or defeat — is consistent with industry data showing that a significant majority of pharmaceutical patent disputes settle before trial, often reflecting confidential licensing terms that serve both parties’ commercial interests.